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Progress was made this period on the important question of how FTI efficacy is achieved in breast cancer. Clinical trials have revealed that breast cancers respond to FTI but only in a minority of cases. What factors dictate FTI efficacy? In this period, we advanced our studies of the role of cyclin B1, a key regulator of mitosis, as a critical target for RhoB suppression in FTI-induced apoptosis. Evidence that cyclin Bl downregulation was critical for FTI-induced tumor suppression was obtained. Mechanistic studies revealed that at early times RhoB suppressed the transcription and the nuclear accumulation of cyclin Bl that occurs in cells destined to undergo FTI-induced cell death. In a second line of work, we discovered that Rho and Myc interact genetically in breast tumor formation. Specifically, we found that loss of RhoB accelerated breast tumor formation in MMTV-c-myc mice. Preliminary studies suggest that this effect may be based increased stability of the c-Myc protein, prompting the hypothesis that RhoB regulates the turnover of c-Myc in cancer cells. Our work furthers the notion that cyclin Bl is a critical proapoptotic target of RhoB and it reveals suggestive ineractions between RhoB and Myc in breast cancer formation.
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Introduction
We proposed to test the hypothesis that RhoB alteration is responsible for mediating FTI action malignant epithelial cells of the breast. Recent studies suggest that prooncogenic Rho proteins play an important role in driving breast cancer, for example, as in highly aggressive inflammatory breast cancers where overexpression of RhoC is a key oncogenic driver 1,2. RhoB is an antioncogenic member of the Rho gene family which regulates cellular actin structure, adhesion, motility, proliferation, and survival 3. RhoB may contribute to the regulation of a signaling cascade that mediates proliferation in response to epidermal growth factor (EGF) 4 , a major mitogen for normal and neoplastic breast cells. Moreover, RhoB has been assigned a specialized role in the intracellular trafficking of the EGF receptor 5.
Recent work in our laboratory has identified RhoB as a key target for alteration by farnesyltransferase inhibitors (FTIs), an experimental class of cancer therapeutics that are being tested in clinical trials for breast cancer treatment 6. In preclinical models, Although the main support has derived from mouse models, there is also more recent evidence that RhoB mediates the antineoplastic FTI response in human breast carcinoma cells or RhoC-transformed human mammary epithelial cells 11
In this research period, we made progress on both aims of our proposal to address an clinically important question that has emerged with the finding that FTIs display efficacy in human breast cancer, namely, what are the factors which dictate efficacy in the minority of breast cancer patients that respond to FTI treatment? Aim 1 of the project was to test whether deletion of the RhoB gene compromised the antitumor response to FTI treatment in mouse models of human breast cancer. At earlier stages of the work this aim was stymied by mouse breeding issues that arose. In this period, we made progress in circumventing this block by changing the mouse model of breast cancer used. In Aim 2, which was refocused with the permission of the USAMRMC given progress on the original aim, we sought to define effector signals involved in mediating FTI-induced apoptosis, based on preclinical evidence that this process is important to in vivo efficacy in mice 10. Recent progress supports a critical role for RhoB in regulating the level and subcellular localization of cyclin B1 in FTI-induced apoptosis.
One point to confirm with regard to this project is that in 2002 the principle investigator was altered from Dr. Li to Dr. Kamasani due to personnel changes in the laboratory.
Body
Aim 1. This aim included mouse breeding experiments to move the null allele from a rhoB "knockout" (KO) mouse onto various 'oncomouse' models for breast cancer that use the mouse mammary tumor virus (MMTV) promoter to drive specific oncogene expression in the mammary gland. However, issues emerged with regard to breeding and tumor formation in the strains we originally planned to use. In this grant period, we were able to overcome this issue using MMTV-c-myc mice, which can be bred successfully to rhoB KO mice.
Interestingly, preliminary work in a small cohort of mice suggests that loss of one or two copies of rhoB gene elevates the incidence of c-myc-driven BRCA formation in this model. Specifically, both MMTV-c-myc;rhoB+/-and MMTV-c-myc;rhoB-/-virgin females exhibit tumor formation at 4-6 months of age, compared to MMTV-myc;rhoB+/+ virgins which remain tumor-free up to one year of age (data not shown). MMTV-cmyc;rhoB+/+ mice exhibit tumor formation at -6 months of age when carried on a multiparous schedule (which elevates expression of the MMTV-c-myc transgene due to estrogen-dependent activation of the MMTV promoter). Therefore, rhoB loss phenocopied c-Myc elevation in terms of the kinetics of tumor formation. The simplest explanation for this effect was that rhoB somehow influenced the expression of c-Myc.
Strikingly, initial investigations of this possibility in our Ela/ras-transformed cell model revealed that the rhoB genotype markedly affected the halflife of c-Myc protein, which increased under conditions of rhoB loss (see Fig. 1 ). We are currently working to confirm this effect in c-myc-transformed mouse mammary cells where rhoB levels are varied by gene deletion or by expression of a rhoB-targeted RhoGAP protein (kindly provided by Y. Zheng, Univ. of Cincinatti School of Medicine). While we have yet to determine the molecular mechanism underlying this effect, it is intriguing to note the evidence that RhoB can promote maturation of endosomal vesicles toward the multivesicle body (H. Mellor, Univ. of Bristol, pers.
comm.), which can deliver cargo to the lysosome for degradation, as well as the evidence that under conditions of overexpression, such as those found in breast cancer, c-Myc may be trafficked to the cytosol for degradation (W. Tansey, Cold Spring Harbor Laboratory, pers. comm.).
As we have shown previously, FTI can modulate RhoB, so the above results offer indirect support of the hypothesis that FTI may modulate breast tumor formation via RhoB. In the next grant period, we will determine whether c-myc-driven breast tumors formed in rhoB heterozygous or null backgrounds are indeed less susceptible to growth inhibition (perhaps due to elevated c-myc expression). We have recently initiated interactions with Johnson and Johnson, Inc., to test whether this effect may be seen using not only the Merck FTI that we have used but also another clinically tested FTI in the compound R1 15777.
6
Aim 2. In the last period, this Aim was refocused on new developments in work to define the determinants for FTI-induced apoptosis, which is known from mouse studies to be critical for drug efficacy 10. The original Aim was to assess a possible role for PRK kinase -a key effector kinase for RhoB signaling -in the FTI response.
Positive support for the hypothesis that RhoB and PRK mediate growth suppression by FTI in epithelial cells was obtained in the last period 11, 12 
Conclusions
Work in this grant period revealed genetic interactions between Rho and Myc in breast cancer. These gene families have major roles in driving tumorigenesis.
Specifically, we have observed that attenuation of RhoB expression (as occurs in many cancers including breast cancers) elevates the stability of the c-Myc protein and promotes the formation of c-Myc-driven breast tumors. This interface is novel, exciting, and significant for its implications in how FTIs may influence via RhoB both breast tumor growth and Myc expression. During this grant period, we also advanced work on how cyclin B1 suppression by RhoB mediates the ability of FTI to kill transformed cells. Specifically, we found that cyclin B1 suppression was critical for the ability of FTI to inhibit the growth of tumor cells. We also identified a posttranslational mechanism of cyclin B1 regulation by RhoB, which involves preferential accumulation of cyclin B1 in the cytosol of cells destined to undergo FTI-induced cell death. This mechanism has importance to basic understanding of the regulation of cyclin B1, a pivotal player in cells. The pattern of cytosolic accumulation observed suggests that RhoB may regulate a 'trafficking-to-trash' pathway. Future work will focus on investigating this process as well as on the ability of RhoB to influence c-myc-driven breast cancer, c-Myc protein stability, and FTI responsiveness of c-myc-driven breast tumors. utility of FTIs may benefit from learning how these agents elicit p53-independent apoptosis in mouse models of cancer. Knockout mouse stud-7, 8). Notably, a gain of RhoB-GG is sufficient to mediate many major ies have established that gain of the geranylgeranylated isoform of the facets of the cellular response to FTI in vitro and in vivo (5, (8) (9) (10) . In small GTPase RhoB is essential for FTI to trigger apoptosis. Here we particular, a genetic proof of the essential role of RhoB-GG in demonstrate that Cyclin B1 is a crucial target for suppression by RhoB in FTI-induced apoptosis has been offered by knockout mouse studies this death program. Steady-state levels of Cyclin B1 and its associated (5) . Reinforcing this line of work, other studies have shown that RhoB kinase CdkI were suppressed in a RhoB-dependent manner in cells fated limits cancer development and that it is critical for the apoptotic to undergo FTI-induced apoptosis. These events were not derivative of cell response of transformed cells to genotoxic stress (11, 12). cycle arrest, because they did not occur in cells fated to undergo FTIOperation of this apoptotic program is widely blunted in human induced growth inhibition. Mechanistic investigations indicated that RhoB mediated transcriptional suppression but also accumulation of cncericell, whc mo s stud is are scptible to gw Cyclin B1 in the cytosol at early times after FTI treatment, at a time inhibition, but not killing, by FTI. This apoptotic impotence may be before the subsequent reduction in steady-state protein levels. Enforcing relevant to clinical experience, which has not tended to recapitulate Cyclin Bi expression attenuated apoptosis but not growth inhibition the dramatic efficacy produced by FT1 in certain preclinical models, triggered by FTI. Moreover, enforcing Cyclin B1 abolished FTI antitumor particularly in Ras transgenic models (13) (14) (15) in which tumor regresactivity in graft assays. These findings suggest that Cyclin BI suppression sions elicited by FTI treatment are associated with induction of is a critical step in the mechanism by which FTI triggers apoptosis and apoptosis (16) . Because one would expect efficacy and cytotoxicity to robust antitumor efficacy. Our findings suggest that Cyclin B1 suppresbe linked, learning how RhoB facilitates FTI-induced apoptosis in sion may predict favorable clinical responses to FTI, based on cytotoxic mouse models may suggest insights into the relative resistance of susceptibility, and they suggest a rational strategy to address FTI nonre-human cancer cells. sponders by coinhibition of Cdkl activity.
Recently, microarray studies identified Cyclin B 1 as a major target for down-regulation by RhoB in transformed mouse cells fated to
INTRODUCTION undergo FTI-induced apoptosis (17). This finding was interesting
Cell suicide processes are thought to play an important role in because of earlier evidence that FTI and RhoB influence G,-M phase limiting cancer progression and therapeutic response. Although great events (12, 18), including Ras-independent control of Cyclin B l/Cdkl progress has been made in identifying the basic mechanisms of activity (19) . We, therefore, tested the hypothesis that the suppression apoptosis, much less is known about transformation-specific mechaof Cyclin B 1 by RhoB may be a critical factor in the ability of FTI to nisms of apoptosis that may relate more directly to cancer pathophystrigger apoptosis. iology. Insights in this area may increase understanding of the pathophysiological roots of cancer progression as well as identify better
MATERIALS AND METHODS
strategies to trigger cancer-selective cell deaths.
Farnesyltransferase inhibitors (FTIs) trigger a unique p53-indeCell Culture. The generation and culture of mouse embryonic fibroblasts pendent apoptosis in transformed mouse and rat cells, in vitro and in (MEFs) transformed by adenovirus EtA and mutant H-Ras has been described vivo, although they have much less effect on the survival of most previously (5, 11). E1A+Ras-transformed MEF cell populations that are nontransformed cells (1, 2). FTIs were developed originally as a heterozygous or nullizygous for RhoB are termed ER +/-or ER -/-cells, strategy to attack the farnesylation requirement of oncogenic Ras in respectively (5). Heterozygous cells, which exhibit similar biological properhuman cancers. However, it has become clear that the response of ties to homozygous wild-type cells (5, 11) , are matched to nullizygous cells to transformed cells to FTIs is based to a significant extent on factors control for the presence of the neomycin resistance cassette used for rhoB gene beyond Ras targeting (3, 4) . For example, it has been demonstrated replacement (11). The specific FTI inhibitor L-744,832 (13) was added to cell cultures to a final concentration of 10 pAmol/L when indicated. In some experiments, the structurally distinct peptidomimetic FTI inhibitors B581 or apoptosis (5). RhoB is unusual among small GTPases in that it exists FTI-277 were used at the same concentration. Generation and culture of the rat intestinal epithelial (RIE) cell line transformed by an oncogenic V12 mutant of Received 7/14/04; revised 9/12/04; accepted 10/6/04. K-Ras, termed RIE/K-ras, has been described previously (8) . MMEC/myc is a (22) . Briefly, cells were seeded at 5 X 105 cells per 48 hours with FTI before fixing and staining with fluorescein-phalloidin well in a 6-well dish and were transfected the next day with 3 j.g of the cyclin (Molecular Probes, Eugene, OR) as described previously (26) . To monitor B I or empty pBabe(puro) vectors. After 48 hours, cells were passaged into Cyclin Bl, we seeded cells onto coverslips in 24-well dishes, and the next day, 100-mm dishes, were treated the following day with 1 tig/mL puromycin, and we replaced the medium with DMEM containing 10% or 0.1% fetal bovine were expanded into mass culture for analysis. Cell populations were screened serum (dictating growth-inhibitory or apoptotic response to FTI, respectively (Promega, Madison, WI) or the cyclin B1 promoter-reporter pGL2-cycB 1-luc Anchorage-dependent proliferation was determined by sulforhodamine B (22) and 0, 0.5, 1, 1.5, or 1.8 Mkg of the HA epitope-tagged RhoB or RhoA (SRB) assay in a 96-well format. Anchorage-independent proliferation was vectors or the corresponding no-insert control vectors that have been described determined in soft agar culture (ER MEFs) or on polyHEMA-coated dishes previously (7, 8, 27 ). The total quantity of DNA in each transfection was (MMEC/myc cells) as described previously (9, 23).
normalized to 3 Mg with empty vector corresponding to the different RhoB Apoptosis. FTIs have previously been shown to induce apoptosis of Rasvectors used (7-9, 27). Cells were harvested 48 hours after transfection and transformed cells under conditions of deprival of serum growth factors or were processed with a commercial kit (Dual Light System, cat. no. BD100LP, substratum attachment (5, 23-25). For serum deprival experiments, 5 X 105 Applied Biosystems, Foster City, CA) and a fluorescence luminometer (Ana-ER MEFs or RIE/K-ras cells were seeded onto 60-mm dishes and were treated lytical Luminescence Laboratory, San Diego, CA). RhoB-GG and Apoptotic Cell Fate. Cyclin B1 expression is re-PBS, were fixed in 70% EtOH, and were analyzed by flow cytometry. stricted normally to G 2 -M phase by a complex set of regulatory events Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) (28). This tight control is profoundly disrupted during malignant assay was performed in some experiments with a commercial kit according to development, as illustrated by aberrant expression patterns of Cyclin the manufacturer's protocol (Roche Molecular Biology, Indianapolis, IN).
B1, including during G, phase in cancer cells (29) . Given the central TUNEL-positive cells in the population were quantitated by flow cytometry role of Cyclin B11 in cell cycle control and cell survival, and its with a FACscan cell analyzer (Becton-Dickinson, San Jose, CA).
profound disruption in transformed cells, one would expect the alterTumorigenicity Assay. Cells were tested for tumorigenic potential in ation of Cyclin B 1 to mediate alterations in the physiology of trans--8-week-old nude mice (Charles River, Cambridge, MA). Mice were given formed cells. This gene was identified previously as a target for injections subcutaneously on the upper thigh of different legs of the same suppression by RhoB in E1A+Ras-transformed cells that were fated animal with 106 cells suspended in 200 MtL of DMEM. Palpable tumors appeared at the injection site within 1 week and visible nodules of >0.5 cm to undergo FTI-induced apoptosis (17). This regulatory connection were apparent by 2 weeks. For FTI trials, mice were dosed once daily when the was selective to transformed cells, because it was not seen in normal tumor reached -50 to 100 mm 3 by intraperitoneal injection with FTI cells. Therefore, we explored its potential significance in E1A+Ras-L-744.832 (40 mg/day) or 30% DMSO carrier in 0.2 mL total volume as transformed cells that were heterozygous or homozygous null for described previously (13) . Tumor volumes were calculated with caliper measrhoB (termed ER +/-or ER -I-cells), with the potent and specific urements and the formula, (width) 2 X length X 0.52. FTI L-744,832 to induce growth inhibition or apoptosis under normalWestern Analysis. Cells were harvested by washing once in PBS before culture conditions or serum-deprival conditions, respectively, as delysis in lX radioimmunoprecipitation (RIPA) buffer supplemented with 10 scribed previously (5). MtL/mL Protease Inhibitor Sets II and III (Calbiochem, San Diego, CA).
FTI caused a rapid and specific reduction in steady-state levels of Cellular protein was quantitated by Bradford assay, and 25 Mg of protein was cyclin B11 in a manner that was associated with the induction of fractionated by SDS-PAGE. Gels were analyzed by standard Western blotting RhoB-GG and apoptotic fate (Fig. 1A) . This response was specific methods with antibodies to Cyclin B 1 (Santa Cruz Biotechnology, Santa Cruz, CA, cat. no. sc-245), Cdkl [Cell Signaling, Beverly, MA; PhosphoPlus Cdc2 (Tyrl5) Antibody kit], Bcl-xL (BD Transduction Laboratories, Los Angeles, through G,-S phase, and S-phase/G 2 phases of the cell cycle, respec-CA; cat. no. 610211), and actin (Santa Cruz Biotechnology, cat. no. sc-1616).
tively) were not affected by FTI treatment. Furthermore, cyclin BI Detection of the primary antibody was carried out with a chemiluminescence was not suppressed under normal-culture conditions in which FTI system for the detection of murine antibodies (Pierce, Rockford, IL). treatment caused growth inhibition but not apoptosis (24, 25). This Cellular Immunofluorescence. Cells were seeded onto coverslips in 24-response was not compound-specific because the same pattern of well dishes and were treated the next day for various times with 10 Amol/L FTI cyclin B 1 suppression was produced by the structurally distinct FTIs B581 and FFI-277 (Fig. 1B) . Under the same conditions, FTI treat-
associated with specific suppression of Cyclin B 1 (Fig. 2A) . A similar RhoB inhibited the activity of the cyclin B1 promoter in a doseanalysis was performed with extracts prepared from cells that were cultured in serumdependent manner (Fig. 3A) . This effect was not phenocopied by the was expressed ectopically (Fig. 3C) . Moreover, an engineered
Western analysis was performed as above with pan-or phospho-specific Cdkl antibodies.
RhoB-GG isoform (9) was sufficient to phenocopy the inhibition In D, suppression of Cyclin B 1 precedes execution of cell death. Western analysis of the caspase-3 indicator protein PARP is shown in extracts prepared from cells treated with elicited by wild-type RhoB plus FTI (Fig. 3C) . The mutant RhoB-C186C (27) to suppress the cyclin B1 promoter. This observation reinforced the conclusion that the ability of FTI to inhibit Cyclin B 1 expression was causally connected to the ability of FTI to kinase that is specifically bound and activated by Cyclin B I (Fig. 1C) . elicit the geranylgeranylated isoform of RhoB in cells. The basis for Cdkl loss was unclear, but it suggested a mechanism A panel of six effector domain mutations with known interaction that focused on the Cyclin B1l/Cdkl complex. The specific reduction properties (8) was used to address the question as to whether the in Cyclin B1 and Cdkl was not derivative of cell death, because pattern of effector interactions differed from those associated with Cyclin Dl and Cyclin A were not affected and because the kinetics of growth inhibition by RhoB-GG [which map significantly to interacCyclin B1/Cdkl reduction preceded the kinetics of poly(ADP-ribose) tions with protein kinase C-related kinase (PRK) (8) ]. No single polymerase (PARP) cleavage, an indicator of caspase-3 activation mutant completely relieved the ability of RhoB-GG to inhibit the during the execution phase of apoptosis (Fig. ID) .
cyclin B1 promoter, suggesting that multiple interactions were needed Cyclin B 1 responded similarly to FTI in other cell systems in which to mediate full inhibition. However, the activity pattern differed neoplastic transformation was driven by FTI-insensitive oncoproteins. markedly from that seen for growth inhibition (8) . In particular, the RIE/K-ras is an RIE rat intestinal epithelial cell line transformed by T37Y and E40T mutants suggested a role for kinectin, a Rho effector the activated K-Ras mutant K-RasG12V (8). FTI does not inactivate protein that binds the microtubule motor kinesin (Fig. 3D ). T37Y is a K-Ras, because this protein is geranylgeranylated in drug-treated cells mutant that abolishes interactions with all Rho effector molecules (30) . Nevertheless, despite the failure to block K-Ras prenylation, FTI except kinesin (31) , and this mutant was even more active than strongly inhibits the proliferation of RIE/K-ras cells in serum-con-wild-type RhoB-GG. In contrast, E40T, which abolishes interactions taining media, an effect that is associated with RhoB-GG induction with kinesin but not with other Rho effector molecules (31), relieved and that can be phenocopied by ectopic expression RhoB-GG (8) . In inhibition by RhoB-GG more strongly than any other mutant. Taken the absence of serum growth factors, we observed that FTI triggers together, these results supported the interpretation that RhoB mediated apoptosis of RIE/K-ras cells, consistent with similar observations in the ability of FTI to suppress Cyclin B1 at a transcriptional level, by other K-Ras-transformed cells (24). As before, apoptotic fate was a mechanism(s) distinct from that used to cause growth inhibition. Cytosolic Accumulation of Cyclin B1 Precedes Suppression of nuclear export. Nuclear export of Cyclin B 1 is mediated by a CRM 1-Protein Levels and Apoptosis. RhoB has a specific physiologic dependent mechanism (35) . However, we found that the CRM1 infunction in signal trafficking as illustrated by its role in trafficking of hibitor leptomycin B 1 did not prevent relocalization of Cyclin B 1 in the epidermal growth factor receptor (EGFR) and Akt (32, 33) . ER +/-cells (data not shown), suggesting that cytosolic accumulation Mistrafficking of these proteins that is elicited by FTI is associated occurred as a result of a block to nuclear import. We concluded that, with induction of RhoB-GG and altered protein turnover. Therefore, at early times after FTI treatment, RhoB impaired the nuclear accualthough Cyclin B 1 had been highlighted by gene microarray analysis, mulation of Cyclin B 1 in cells that were fated to undergo apoptosis. we were interested in learning whether RhoB might influence its Enforcing Cyclin B1 Expression Limits RhoB-Dependent Apotrafficking in transformed cells. As mentioned above, although Cyclin ptosis Triggered by FTI. We reasoned that if cyclin B 1 suppression B1 is restricted to G 2 -M phase in normal cells, its regulation is was essential for Fli-induced apoptosis, then overexpressing cyclin profoundly disrupted in neoplastic cells, in which inappropriate nu-B 1 to combat its down-regulation might reduce apoptotic susceptibilclear expression of Cyclin B1 can be observed broadly in the cell ity of ER +/-cells. Conversely, we reasoned that reducing cyclin B1 cycle including in G, phase (e.g., see refs. 29, 34) . ElA+Ras-expression would elevate the sensitivity of ER -/-cells to FTItransformed cells have been used widely as a cancer model, and induced apoptosis. To test these predictions, we compared the FTI consistent with the human cancer cell studies, we observed wide-response in ER +/-cells in which Cyclin B1 was augmented by spread constitutive nuclear expression of Cyclin B 1 in unsynchroectopic expression, and in ER -/-cells in which Cyclin B I levels were nized cell populations (see below and Discussion).
reduced by an RNAi strategy. As a control for apoptosis suppression, To assess the effects of RhoB on the localization of Cyclin B 1, we we overexpressed the antiapoptotic protein Bcl-xL in ER +/-cells. used indirect immunofluorescence to examine the status of Cyclin B 1
Using a human cyclin B1 vector (22), we achieved a several-fold in ER +/-and ER -/-cells treated 8 hours with FTI under conditions increase in steady-state levels of Cyclin B1 protein in ER +/-cells in which cell fate was directed to either growth inhibition or apoptosis (Fig. 5) . FTI treatment of these cells (ER +/-cycB I cells) still led to (Fig. 4) . This time point was early in the FTI response, within the time a reduction in steady-state levels of Cyclin B 1, but only to the level of that RhoB-GG was induced but before any reduction occurred in the expression that was characteristic of untreated vector control cells (ER steady-state levels of Cyclin B 1 (Fig. 1A) or induction of the effector +/-vect cells). This observation was consistent with evidence that phase of apoptosis (Fig. 1D) . Two observations were made. First, we RhoB affected Cyclin Bl at more than at a transcriptional level (as observed widespread and robust nuclear expression of Cyclin B 1 suggested by the microarray analysis). From a functional standpoint, throughout the unsynchronized ER cell population, regardless of rhoB the ER +/-cycB 1 cells were acceptable to test our hypothesis, begenotype, arguing that ElA+Ras transformation profoundly dis-cause the steady-state level of Cyclin B 1 in FTI-treated cells persisted rupted the normal regulation of Cyclin B 1. Second, we observed that to levels that were similar to those found in untreated ER +/-vector FlI induced a punctate cytosolic accumulation of Cyclin B 1 in cells cells. An effect of exogenous Cyclin B I was also reflected on steadyfated to undergo apoptosis (Fig. 4) . This event was not associated with state levels of Cdkl and phosphorylated (active) Cdkl, which were growth inhibition, because Cyclin BI did not relocalize in cells fated elevated in ER +/-cycBl cells toward the levels of untreated control to undergo growth inhibition. Moreover, it depended on the ability of cells (Fig. 5A) . We noted that Bcl-xL also elevated the level of FTI to elicit RhoB-GG because relocalization did not occur in ER endogenous cyclin B1 and Cdkl, hinting at some level of cross-talk in -/-cells in which RhoB-GG could not be induced. The change in this system that was mechanistically undefined. Cyclin B1 localization could conceivably occur in one of two ways, Overrexpressed Cyclin B1 specifically inhibited the apoptotic reeither by imposing a block to nuclear import or by potentiating sponse of ER +/-cells to FTI treatment. Under normal culture con-8392 the ER +/-cycB 1 tumors were completely resistant to FTI (Fig. 6A ).
in low serum conditions for 24 hours before normalized luciferase activity was determined
The germane effect of Cyclin B 1 on the in vivo response to FTI in cell extracts 48 hours after transfection. Error bars, the SD of the data. In A, RhoB treatment was apparent when the data were internally normalized to inhibits the activity of the cyclin B 1 promoter. In B, inhibitory effect of RhoB is not phenocopied by RhoA, which activates the cyclin B I promoter. In C, RhoB-GG phenocontrol for the growth effect of Cyclin B 1 (Fig. 6B) . We concluded copies the ability of RhoB + FTI to inhibit the cyclin BI promoter. RhoB vectors were that the suppression of Cyclin B 1 mediated by RhoB was critical for transfected at a 5:1 ratio to the cyclin BI luciferase reporter plasmid in this experiment. The mutant RhoB-C 186S is unprenylated and inactive because of loss of the cysteine in FTI efficacy in this system.
the CaaX prenylation motif (7) . In D, effector domain mutations in RhoB-GG identify a correlation between cyclin BI promoter inhibition and interaction with the Rho-binding protein kinectin (see Results). RhoB vectors were transfected at a 5:1 ratio to the cyclin BI luciferase reporter plasmid in the experiment.
Growth inhibition fate Apoptotic fate DAPI Anti-cyc81 DAPI Anti-cycB1 ditions, ER +/-cells respond to FTI by undergoing morphologic reversion, stress fiber formation, and growth inhibition (5); and enforced cyclin B1 expression did not alter the pattern of these reControl sponses. FTI-induced actin stress fiber formation was not affected ER (data not shown). RhoB-GG is sufficient and necessary to mediate this +/-response (5), so the ability of FTI to induce stress fibers in ER + Ft' +/-cycB 1 cells confirmed that enforced Cyclin B11 did not interfere 8h with the induction of a functionally competent RhoB-GG molecule. Similarly, neither enforced cyclin B 1 nor Bcl-xL blocked the ability of FTI to cause growth inhibition under anchorage-independent conditions (Fig. 5B) . In contrast, enforced cyclin B1 and Bcl-xL each inhibited the apoptotic response of ER +/-cells to FTI treatment that Control was manifested under serum-deprived conditions, as documented by ERl TUNEL assay and flow cytometry (Fig. 5C ). This observation sug-I/I gested that Cyclin B11 responded downstream of RhoB in the pro-+ FTI apoptotic mechanism elicited by FTf. In the converse experiment, we 8h found that small interfering RNA (siRNA)-mediated blockade of cyclin Bl expression in ER -/-cells was not tolerated in stably transfected cell populations. Two cell populations that stably inte- cells, but these cell populations proliferated poorly and were unstable permeabilized, and were processed for indirect immunofluorescence with an anti-Cyclin (data not shown). This result was unsurprising, given the requirement BI antibody (Anti-cycBl). DAPI costaining was used to visualize nuclei. 8393 ER +1-bcl-xL bers of the RhoB "traffickome" include the EGFR and the survival kinase Akt, two important regulators of neoplastic cell growth and survival (32, 33) . The findings of this study suggest that trafficking of Cyclin B1 may also be subjected to control by RhoB under certain stress conditions, including those present in transformed cells. Thus, RhoB may influence susceptibility to proapoptotic stimuli by influencing how signaling molecules are trafficked under stressful condi-! tions (e.g., "trafficking to survive" versus "trafficking to trash"). In support of the concept that signal trafficking may influence apoptotic susceptibility, another study has defined an essential role for Binl1 Amphiphysin2 [a BAR adapter-encoding gene implicated in vesicle trafficking processes and cancer suppression (40-45)] in FTI-induced apoptosis (46) . The present work develops the model that alteredsignal trafficking can alter apoptotic susceptibility to FTI. If selection suppressing Cyclin B1 is critical to antitumor activity, in support of Cells (10') were injected subcutaneously into nude mice, and tumor volume was deterother evidence that apoptosis is critical to in vivo antitumor efficacy mined by caliper measurements at times afterward (n = 5). B, relative effect of FTI on tumor growth at 2 weeks. The data were internally normalized to each cell line to control (5, 14, 16) . In the one study that has reported FTI effects on cyclin B I for the apparent growth effect of Cyclin B I (cycB1) on tumor growth. Error bars, SD of in human cancer cells, it was found that growth inhibition was the data. (vect, vector.) 8394
